Exercise Stress Tests Can Also Predict Noncardiovascular Deaths
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 14, 2023 -- Abnormalities on an exercise stress test can predict both cardiovascular (CV)- and non-CV-related deaths, according to a study published in the September issue of Mayo Clinic Proceedings.
Nóra Sydó, M.D., Ph.D., from Semmelweis University in Budapest, Hungary, and colleagues sought to identify specific causes of death and determine the prevalence of non-CV deaths in an exercise test referral population and to assess whether exercise test parameters predict non-CV as well as CV deaths. The analysis included nonimaging exercise tests from 13,382 patients (30 to 79 years; September 1993 to December 2010) with mortality determined through January 2016 via Mayo Clinic records and the Minnesota Death Index.
The researchers found that risk for non-CV death was significant for low functional aerobic capacity (hazard ratio, 1.42), abnormal heart rate recovery (hazard ratio, 1.36), and low chronotropic index (hazard ratio, 1.49). An abnormal exercise electrocardiogram (ECG) was not a significant risk. There was a stronger association observed between all exercise test abnormalities, including a composite exercise test score (EX_SCORE), and CV death versus non-CV death, except abnormal exercise ECG.
"Patients should be encouraged to increase physical activity if these prognostic parameters are abnormal, even in the absence of substantial ECG-based CV risk," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
342 Cardiology Clinics Acquired by Private Equity Firms in 2013 to 2023
WEDNESDAY, July 3, 2024 -- From 2013 to 2023, 342 cardiology clinics were acquired by private equity firms, with 94.7 percent of the acquisitions occurring between 2021 and 2023...
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.